News & Events

Fluid-based accommodating IOL yields strong visual acuity in sighted eyes

BOSTON — A fluid-driven accommodating IOL yielded promising results in early clinical trials, a speaker said here.

Louis D. "Skip" Nichamin, MD, presented results of a phase 2 clinical trial for the FluidVision accommodating IOL (PowerVision) at the American Society of Cataract and Refractive Surgery meeting.

The study was the first involving the lens implanted in sighted eyes. A phase 1 trial tested accommodative motion in severely glaucomatous eyes, Dr. Nichamin said.

"Our early results in the very first sighted eyes to be implanted with the FluidVision lens are showing excellent visual acuity in general and offer an average greater than 5 D of accommodative power by the way of internal movement," Dr. Nichamin said. "The FluidVision lens mimics the natural accommodative process of our crystalline lens with a shape change and forward movement. This is all achieved through a standard technique."

The trial included six patients who underwent lens implantation. Primary outcome measures were visual acuity testing and accommodative response. Optical coherence tomography was used to measure the range of accommodative movement.

Results showed that all patients had postoperative visual acuity of 20/20 or better, and all were within 1 D of emmetropia. The lens provided an average of 5.6 D of accommodative power. Three patients had 6.5 D of accommodation, Dr. Nichamin said.

OCT imaging showed that average internal lens movement was 100 µm at 3 months postoperatively. That movement correlated with 5 D to 6 D of accommodation.

Investigators plan to implant the lens in a total of 20 eyes and hope to have an injectable delivery system later this year. The next generation FluidVision lens may have the potential to improve accommodative power by 50%, Dr. Nichamin said.

Return to News...